ArticleCellular and molecular neurobiology2026
5-Hydroxytryptamine 6 Receptor Antagonism Ameliorates Depression-Like Behaviors in Temporal Lobe Epilepsy Rats with Potential Involvement of the MEF2C/NF-κB Pathway.
Article in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate whether 5-HT6 receptor (5-HT6R) antagonism could ameliorate epilepsy-associated emotional and behavioral disturbances in rats with temporal lobe epilepsy (TLE) and to explore its potential association with the MEF2C/NF-κB pathway. Thirty rats were randomly divided into normal control (NC) group, Model group and 5-HT6R group. The TLE model was established using lithium chloride-pilocarpine. The rats in 5-HT6R group were treated with 5-HT6R antagonist SB271046. Behavioral tests were conducted to evaluate anxiety- and depression-like behaviors associated with epilepsy. Levels of inflammatory factors, 5-HT and KYN in hippocampal tissues were detected by enzyme-linked immunosorbent assay. Neuronal cell death in brain tissues was assessed by TUNEL staining, and the protein expressions of MEF2C and NF-κB p65 were measured by Western blotting. Molecular docking between SB271046 and MEF2C/NF-κB p65 was performed using AutoDock 4. In addition, JASPAR database was used to analyze the putative binding of CREB1 to MEF2C promoter. Rats in the Model group exhibited significant epilepsy-associated anxiety- and depression-like behaviors, accompanied by aggravated inflammation, decreased MEF2C protein expression and increased NF-κB p65 protein expression. Treatment with SB271046 significantly ameliorated these behavioral abnormalities and inflammatory responses, and was associated with upregulated MEF2C protein expression and downregulated NF-κB p65 protein expression. KEGG enrichment analysis suggested the involvement of NF-κB pathway in TLE. Molecular docking revealed potential interactions between SB271046 and MEF2C/NF-κB p65. 5-HT6R antagonist SB271046 may alleviate epilepsy-associated emotional and cognitive disturbances, potentially through neurostabilizing and anti-inflammatory effects linked to modulation of the MEF2C/NF-κB pathway. These mechanistic associations remain preliminary and warrant further validation using targeted gain- or loss-of-function approaches.
Indexed as
Identifiers
42911284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.